TruSkin®: Study for Treatment of Chronic Venous Leg Ulcers

NCT ID: NCT02936128

Last Updated: 2017-04-06

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-07-31
• Study Completion Date: 2017-04-30

Brief Summary

The purpose of this study is to compare the clinical outcomes of TruSkin® and an Active Comparator in patients with chronic venous leg ulcers.

Conditions

Chronic Venous Leg Ulcers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

TruSkin®

Cryopreserved skin allograft

Group Type: EXPERIMENTAL

TruSkin

Intervention Type: OTHER

Wound Cover

Active Comparator for Venous Leg Ulcers

Group Type: ACTIVE_COMPARATOR

Wound Cover

Intervention Type: OTHER

Interventions

TruSkin

Intervention Type: OTHER

Wound Cover

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Between 18 years and 80 years of age inclusive, as of the date of screening

2. An Index Ulcer that is chronic (defined as present for > 4 weeks, but not present for more than 52 weeks at the Screening Visit)

3. Index Ulcer is located on the leg, below the knee

4. The Index Ulcer is a Venous Leg Ulcer (VLU) greater than 10 cm2, inclusive, at the Screening Visit

5. The longest length and longest width measurements for the Index Ulcer are no less than 1 cm each at the Screening Visit

6. The Index Ulcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone, or joint capsule

7. Wound is free of necrotic debris

8. Patient has adequate circulation to the foot as documented by Ankle Brachial Index (ABI) or Toe Brachial Index (TBI)

9. Confirmed diagnosis of venous insufficiency with duplex ultrasonography to demonstrate reflux of ≥ 0.5 seconds in the superficial lower extremity venous system.

Exclusion Criteria

1. Index Ulcer is of non-venous pathophysiology

2. Gangrene is present on any part of the affected limb

3. Patient is currently receiving dialysis or planning to go on dialysis

4. Patient has a glycated hemoglobin A1c (HbA1c) level of >12%

5. Chronic oral steroid use >7.5 mg daily for longer than 3 months at the time of screening

6. Patient is receiving IV corticosteroids, immunosuppressive or cytotoxic agents at the time of screening

7. Requiring intravenous (IV) antibiotics to treat the index wound infection at the time of screening

8. Patient has an ulcer within 5 cm of the Index Ulcer identified for study consideration

9. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS)

10. Current evidence of cellulitis, or other evidence of infection including fever or pus drainage from the wound site

11. Current evidence of osteomyelitis or history of osteomyelitis within 30 days of screening

12. Patient has active malignancy other than non-melanoma skin cancer

13. Patient's Index Ulcer has decreased by ≥ 20% during 1-week screening period

14. Patient's random blood sugar is > 450 mg/dl at screening

15. Patient is unable to receive compression therapy as a part of standard of care

16. Patient has untreated alcohol or substance abuse at the time of screening

17. Pregnant women and women who are breastfeeding

18. Patient is currently enrolled or participated in another investigational device, drug, or biological trial within 30 days of screening

19. Patient has had within the last 30 days, or is currently undergoing, or is planning for wound treatments with growth factors, living skin, dermal substitutes or other advanced biological therapies

20. Patient is an employee, or an immediate family member of an employee, of the sponsor company or site research staff conducting the study

21. Patients who have already been randomized in Protocol 352 at any center may not be considered for screening or for re-entry into the trial at any center, even after the End of Study Visit

22. Patients with a history of poor compliance, or an unwillingness or inability to adhere to the requirements of the protocol

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Osiris Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

California City, California, United States

Florida City, Florida, United States

Massachusetts, Massachusetts, United States

Michigan, Michigan, United States

North Carolina, North Carolina, United States

Pennsylvania, Pennsylvania, United States

Virginia City, Virginia, United States

Countries

United States

Other Identifiers

Osiris Protocol 352

Identifier Type: -

Identifier Source: org_study_id